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Abstract
Background: We have previously demonstrated that the hydroxylated biphenyl compound D6 (3E,3′E)
-4,4′-(5,5′,6,6′-tetramethoxy-[1,1′-biphenyl]-3,3′-diyl)bis(but-3-en-2-one), a structural analogue of curcumin, exerts a
strong antitumor activity on melanoma cells both in vitro and in vivo. Although the mechanism of action of D6 is yet
to be clarified, this compound is thought to inhibit cancer cell growth by arresting the cell cycle in G2/M phase, and
to induce apoptosis through the mitochondrial intrinsic pathway. To investigate the changes in protein expression
induced by exposure of melanoma cells to D6, a differential proteomic study was carried out on D6-treated and
untreated primary melanoma LB24Dagi cells.
Methods: Proteins were fractionated by SDS-PAGE and subjected to in gel digestion. The peptide mixtures were
analyzed by liquid chromatography coupled with tandem mass spectrometry. Proteins were identified and quantified
using database search and spectral counting. Proteomic data were finally uploaded into the Ingenuity Pathway
Analysis software to find significantly modulated networks and pathways.
Results: Analysis of the differentially expressed protein profiles revealed the activation of a strong cellular stress
response, with overexpression of several HSPs and stimulation of ubiquitin-proteasome pathways. These were
accompanied by a decrease of protein synthesis, evidenced by downregulation of proteins involved in mRNA
processing and translation. These findings are consistent with our previous results on gene expression profiling in
melanoma cells treated with D6.
Conclusions: Our findings confirm that the curcumin analogue D6 triggers a strong stress response in melanoma cells,
turning down majority of cell functions and finally driving cells to apoptosis.
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Background
Malignant melanoma (MM) is the most aggressive skin
cancer, and its incidence has dramatically risen in all
Western countries during the last half century [1].
Although most melanoma cases are early diagnosed and
surgically resected, until recently later stages had very
poor survival rates because of the lack of effective
therapies [2]. In very recent years, several therapeutic
approaches - including immune-targeted treatments
(anti-CTLA4 agent ipilimumab, anti-PD-1 agent nivolu-
mab, and anti-PD-L1 agents such as lambrolizumab) or
inhibitors of key effectors of the MAPK pathway
(BRAF-mutant inhibitors as vemurafenib or dabrafenib,
MEK inhibitors as cobimetinib, trametinib, and their com-
bination) - are allowing to overcome the ineffectiveness of
the conventional therapies and achieve an impressive im-
provement of the patients’ survival [3, 4]. However, tumor
responses produced by the main targeted inhibitors are
largely partial and tumor resistance typically develops in
few months as a consequence of the activation of alterna-
tive proliferation-inducing pathways [5, 6]. Since it is thus
unlikely that inhibition of a single component in signaling
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pathways could yield significantly durable antitumor
responses, drug combinations are awaited for a more
effective anti-tumor therapy.
Natural products have afforded a rich source of com-
pounds that have found many applications in cancer
therapy [7]. Among such products curcumin, a polyphe-
nol extracted from the rhizome of the plant Curcuma
longa, represents an interesting and promising antican-
cer therapeutic compound. It is a highly pleiotropic mol-
ecule that causes inhibition of proliferation, invasion,
angiogenesis, and metastasis in several types of cancer
through interaction with multiple cell signaling proteins [8].
We have previously characterized the antitumor
activity exerted by a curcumin analogue called D6 on
melanoma cells (Fig. 1). This compound was able to
inhibit cell proliferation and induce apoptosis on melan-
oma cell lines. Tests in vivo showed that D6 could re-
duce tumor growth on melanoma mice models [9]. We
also demonstrated that D6 caused a G2/M arrest of cell
cycle and microarrays gene expression profiling of D6
treated melanoma cells showed the presence of import-
ant changes in gene expression. Results of this analysis
pointed out the induction of strong cell stress responses,
with up regulation of several heat shock proteins (HSPs)
and involvement of protein ubiquitination and stress
response pathways, including p53 driven pathways,
strongly supporting the pro-apoptotic activity previ-
ously observed. Cell proliferation pathways were in-
stead down-modulated [10].
Proteomic approaches enable an in-depth charac-
terization of global changes occurring at a protein level.
One-dimensional polyacrylamide gel electrophoresis is
widely used as fractionation step prior to liquid
chromatography-tandem mass spectrometry to reduce
sample complexity, with remarkable performance in terms
of proteome coverage and the added advantage of main-
taining information concerning protein molecular weight
[11, 12]. Among proteomic quantitation methods, label-
free strategies have proven to be more cost-effective, time-
saving and flexible compared to labeling techniques, al-
though being less accurate for low-abundance protein
[13–15]. The spectral counting approach, in particular,
builds on the observation that the number of tandem
mass spectra detected in data-dependent acquisition for a
given protein are proportional to the protein amount [16].
In order to investigate on the changes induced by D6
at the proteome level and to verify if and to what extent
mRNA expression changes relate to protein expression
changes, a label-free differential proteomic analysis was
carried out on the MM cell line LB24Dagi treated with
D6. Results of such analysis are described in this paper.
Methods
Reagents
The curcumin analogue D6 (3E,3′E)-4,4′-(5,5′,6,6′-
tetramethoxy-[1,1′-biphenyl]-3,3′-diyl)bis(but-3-en-2-one)
(Fig. 1) was synthesized in our lab as previously described
[9]. For melanoma cell treatment, D6 stored as 100 mM
stocks in dimethyl sulfoxide (DMSO) was diluted in
complete medium to contain <0.1 % DMSO, immediately
before use.
Cell cultures and D6 treatments
The melanoma cell line LB24Dagi (LB) was kindly pro-
vided by the “Istituto Dermopatico dell’Immacolata” in
Rome. It was chosen among primary short term cell
cultures established from tumor samples of donor
patients with proven diagnosis of melanoma, as previ-
ously reported [17]. In particular, all primary melanoma
cell lines, including the LB one, were generated from
surgically-excised tumor tissues, using standard pro-
cedures for in vitro isolation and propagation of cells
from dissected tumor samples. Briefly, micro-dissections
of tumor tissues were incubated with specific growth
medium containing gentamicin (50 mcg/ml), fungizone
(2.5 mcg/ml), and DNase I (1 U/ml). For all melanoma
cell lines, tumor tissues were processed after obtaining
the patient’s informed consent and according to the
approval by the Ethics Committee at the “Istituto
Dermopatico dell’Immacolata” in Rome.
The LB24Dagi MM cells were cultured in RPMI sup-
plemented with 10 % FBS and penicillin/streptomycin
[100 IU (50 μg)/ml] in a humidified 5 % CO2 atmos-
phere at 37 °C, either alone or in the presence of 10 μM
D6 for 24 h. Cells were then harvested and washed with
PBS, and the pellets (107 cells each) were stored at −80 °C
Fig. 1 D6 (3E,3′E)-4,4′-(5,5′,6,6′-tetramethoxy-[1,1′-biphenyl]-3,3′-
diyl)bis(but-3-en-2-one). Molecular structure
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pending analyses. The experiment, including both 10 μM
D6 treated and untreated cells, was carried out in tripli-
cate, finally obtaining six cell pellets.
Protein extraction and quantification
Proteins were extracted as follows. Cell pellets were re-
suspended in the 2-D Protein Extraction Buffer V from
GE Healthcare (Little Chalfont, UK; 100 μl buffer per
2.5 × 106 cells) and sequentially subjected to vortexing
(two cycles comprising incubation on ice for 5 min
followed by vortexing for 30 s), freeze-thawing (two
cycles comprising incubation at −80 °C for 15 min
followed by thawing at RT for 15 min) and sonication
(ten cycles comprising sonication in a Transsonic Digital
ultrasonic bath (Elma Electronic, Wetzikon, Switzerland)
for 1 min followed by incubation on ice for 30 s). Finally,
samples were centrifuged for 15 min at 16,000 × g at 4 °C,
and the protein containing supernatant was quantified
using the Bradford method [18].
SDS-PAGE, in gel digestion and liquid
chromatography-tandem mass spectrometry
Thirty micrograms of each protein extract were sepa-
rated by SDS-PAGE in 4–20 % TGX gels (Bio-Rad,
Hercules, CA, USA) and stained with SimplyBlue
SafeStain (Invitrogen, Carlsbad, CA, USA), according to
the manufacturer instructions. Then, each whole lane
was fractionated into 35 gel slices, which were destained,
reduced, carbamidomethylated, and trypsin digested as
described previously [19].
LC-MS/MS analyses were performed on a Q-TOF
hybrid mass spectrometer equipped with a nano lock
Z-spray source, and coupled on-line with a capillary
chromatography system CapLC (Waters, Manchester,
UK), as described elsewhere [19].
Data analysis
Proteome Discoverer Mass Informatics Platform (version
1.4; Thermo Scientific) was used for protein/peptide
identification, using a workflow consisting of the
following nodes (and respective parameters): Spectrum
Selector (precursor mass range: 350–5000 Da; S/N
Threshold: 1.5), Sequest-HT as search engine (Protein
Database: UniProtKB/SwissProt, release 2014_10, tax-
onomy Homo sapiens; Enzyme: Trypsin; Max. missed
cleavage sites: 2; Peptide length range 5–50 amino acids;
Max. Delta Cn: 0.05; Precursor mass tolerance: 10 ppm;
Fragment mass tolerance: 0.02 Da; Static modification:
cysteine carbamidomethylation; Dynamic modification:
methionine oxidation), and Percolator for peptide valid-
ation (FDR <1 %, based on peptide q-value). Protein
grouping was allowed according to the maximum parsi-
mony principle.
The Normalized Spectral Abundance Factor (NSAF)
was calculated in order to estimate protein abundance
[20]. Specifically, a spectral abundance factor (SAF) was
obtained by dividing the number of spectral counts
(SpCs) of a protein by its number of amino acids [21];
then, NSAF values were obtained by dividing the SAF
values by the SAF sum for all proteins identified in each
sample [20]. NSAF values were finally multiplied by a
scale factor corresponding to the average number of
SpCs identified per sample (in order to deal with inte-
gers). The beta-binomial test (along with correction for
multiple testing) was applied to identify statistically sig-
nificant variations between sample groups (FDR <0.05).
Protein fold-change was calculated by dividing the mean
NSAF values for a given protein in one sample group by
the mean NSAF values for that given protein in the
other sample group, using a correction factor (CF = 2) to
eliminate discontinuity due to missing values; fold-
change values that were less than one were replaced by
the negative of their inverse. Percentage coefficient of
variation (%CV) was also measured for each protein
based on mean and standard deviation of NSAF values.
Besides having an FDR <0.05, two further filters
(fold-change >1.3 or <−1.3 and %CV lower than the per-
centage change corresponding to the fold change) were
established to define a significantly differential protein.
Data were parsed using in-house scripts, and graphs were
generated using Microsoft Excel. Network and pathway
analysis were carried out using Ingenuity Pathways
Analysis (IPA, version 9.0, Ingenuity Systems, Redwood
City, CA), considering both direct and indirect relation-
ships and using protein fold-change >1.3 (or <−1.3) and
FDR <0.05 as cut-off.
Results
Differential label-free proteomic analysis
Proteomic analysis allowed the overall identification of
903 proteins, of which 756 in the control (untreated
MM cells) and 630 in the 10 μM D6 treated MM cells
(Additional file 1: Table S1 and Additional file 2: Table S2,
respectively).
A label-free, spectral counting approach was employed
to identify differentially expressed proteins, and thus to
focus on changes in protein expression induced by D6
treatments. Using FDR <0.05 as significance threshold
and fold-change >1.3 or <−1.3 as differential abundance
threshold, 18 and 16 proteins were found as up- and
down-regulated by D6 treatments, respectively (Tables 1
and 2). Most of these 34 selected proteins could be clas-
sified into two major groups according to the putative
kind of cell process they are related (Fig. 2), as listed in
Table 3. The first group comprises about half of the
modulated proteins (47 %), all involved in cell stress re-
sponse, namely: heat shock proteins (HSP)/chaperonins
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Table 1 Upregulated proteins
Accession Gene symbol Protein name Fold-change treated/control FDR
P0CG48 UBC Polyubiquitin-C 6.32 0.00000
P61604 HSPE1 10 kDa heat shock protein, mitochondrial 5.82 0.00001
P08107 HSPA1/HSP70 Heat shock 70 kDa protein 1A/1B 4.97 0.00007
P62318 SNRPD3 Small nuclear ribonucleoprotein Sm D3 4.20 0.00325
P25685 DNAJB1 DnaJ homolog subfamily B member 1 3.72 0.00706
P23396 RPS3 40S ribosomal protein S3 3.72 0.00325
Q92598 HSPH1 Heat shock protein 105 kDa 3.51 0.00080
P04264 KRT1 Keratin, type II cytoskeletal 1 3.42 0.04177
P62258 YWHAE 14-3-3 protein epsilon 3.38 0.03245
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 3.05 0.04582
P63104 YWHAZ 14-3-3 protein zeta/delta 2.89 0.00730
P34931 HSPA1L Heat shock 70 kDa protein 1-like 2.82 0.00371
P07195 LDHB L-lactate dehydrogenase B chain 2.70 0.03245
P17066 HSPA6 Heat shock 70 kDa protein 6 2.58 0.02396
P68363 TUBA1B Tubulin alpha-1B chain 2.39 0.01570
P48741 HSPA7 Putative heat shock 70 kDa protein 7 2.36 0.04329
P04792 HSPB1 Heat shock protein beta-1 2.27 0.01149
P62805 HIST1H4A Histone H4 1.52 0.00054
The table lists the proteins that showed to be upregulated (fold-change >1.3) in LB24Dagi MM cells after 24 h of 10 μM D6 treatments (FDR <0.05). Proteins
modulated also at the gene expression level are shown in bold characters [10]
Table 2 Downregulated proteins
Accession Gene symbol Protein fold-change treated/control FDR
P83731 RPL24 60S ribosomal protein L24 −4.14 0.00054
P61254 RPL26 60S ribosomal protein L26 −3.63 0.02751
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M −3.24 0.00004
P18621 RPL17 60S ribosomal protein L17 −3.11 0.02499
O60506 SYNCRIP Heterogeneous nuclear ribonucleoprotein Q −2.89 0.04096
P62280 RPS11 40S ribosomal protein S11 −2.73 0.00944
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B −2.41 0.02471
P16104 H2AFX Histone H2AX −2.36 0.00054
P13667 PDIA4 Protein disulfide-isomerase A4 −2.05 0.04384
P16104 H2AFZ Histone H2A.Z −1.99 0.00109
Q93077 HIST1H2AC Histone H2A type 1-C −1.92 0.00096
P04908 HIST1H2AB Histone H2A type 1-B/E −1.77 0.00165
P20671 HIST1H2AD Histone H2A type 1-D −1.75 0.01570
Q92841 DDX17 Probable ATP-dependent RNA helicase DDX17 −1.63 0.00109
Q9UKM9 RALY RNA-binding protein Raly −1.47 0.00531
Q9Y6E2 BZW2 Basic leucine zipper and W2 domain-containing protein 2 −1.31 0.00531
The table lists the proteins that showed to be downregulated (fold-change <−1.3) in LB24Dagi MM cells after 24 h of 10 μM D6 treatments (FDR <0.05). Proteins
modulated also at the gene expression level are shown in bold characters [10]
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and other proteins involved in endoplasmic reticulum
(ER) protein processing [22, 23]; ubiquitin, related to
protein degradation process [24]; histones H2AX and
H2AZ both involved in DNA repair [25–27], and others
possibly playing a role in stress response [28–30]. More-
over, the YWHAE and YWHAZ isoforms of the 14-3-3
protein, widely involved in signal transduction, could be
included in this functional group because of their
activity in regulation of cell proliferation and survival as
a response to stress stimuli [31]. Most of these proteins
showed to be upregulated by D6 treatment indicating ac-
tivation of cell defense processes. The second group
representing one-third of the differentially abundant
proteins includes proteins involved in the mRNA pro-
cessing and protein translation machinery [32–39],
mostly showing to be downregulated. The decrease in
abundance of proteins within this major functional
group suggests a reduction of both translation and
protein synthesis in the cells, which can be interpreted
as a sign of cell growth arrest.
The remaining seven regulated proteins exert various
functions: Keratin 1 (KRT1) and Tubulin α-1b (TUBA1B)
represent structural proteins [40, 41] while HIST1H4A,
HIST1H2AB HIST1H2AC, HIST1H2AD all belong to the
Fig. 2 Major functional classification of differentially abundant proteins. The graph represents the major functional groups comprising the 34
proteins identified by differential analysis, as listed in Table 3
Table 3 Major functional classification of differentially abundant proteins
Stress response mRNA processing/translation Others
1 UBC [24] ↑ 1 SNRPD3 [33] ↑ 1 KRT1 [40] ↑
2 HSPE1 [22] ↑ 2 GNB2L1 [36] ↑ 2 LDHB [43] ↑
3 HSPA1/HSP70 [22] ↑ 3 RPL24 [32] ↓ 3 TUBA1B [41] ↑
4 DnaJ B 1 [22] ↑ 4 RPL26 [32] ↓ 4 HIST1H4A [42] ↑
5 RPS3 [28] ↑ 5 HNRNPM [34] ↓ 5 HIST1H2AC [42] ↓
6 HSPH1 [22] ↑ 6 RPL17 [32] ↓ 6 HIST1H2AB [42] ↓
7 YWHAE [31] ↑ 7 SYNCRIP [35] ↓ 7 HIST1H2AD [42] ↓
8 YWHAZ [31] ↑ 8 RPS11 [32] ↓
9 HSPA1L [22] ↑ 9 DDX17 [37] ↓
10 HSPA6 [22] ↑ 10 RALY [38] ↓
11 HSPA7 (HSP90AA1) [22] ↑ 11 BZW2 [39] ↓
12 HSPB1 [22] ↑
13 PPIB [29] ↓
14 H2AFX [26] ↓
15 PDIA4 [30] ↓
16 H2AFZ [27] ↓
Proteins in the table are grouped according to their putative role in our model. Each protein is identified by the corresponding gene symbol. Up- or down-facing
arrows indicates up- or down-regulated proteins, respectively
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replication-dependent histone family [42]; finally, LDHB is
a lactate dehydrogenase subunit participating in pyruvate
to lactate interconversion [43].
On general scale, the protein expression changes par-
tially reflect the biological effects previously observed on
D6-treated LB24Dagi cells: activation of cell stress re-
sponses accompanied by arrest of both cell growth and
cell functions [9, 10].
Functional annotation and pathway analysis
The differential proteomic profiles obtained upon com-
parison of D6 treated and untreated MM cells were ana-
lyzed by the Ingenuity Pathway Analysis (IPA) software,
focusing on statistically differential proteins (FDR <0.05).
Table 4 lists the most significant biological functions
and diseases that appeared to be influenced by D6 activity,
based on the protein abundance changes induced by D6
Table 4 IPA top bio functions and diseases
Top bio functions and diseases p-value # molecules
1 Cellular Compromise 2.26E-06 - 4.58E-02 7
2 Cellular Function and Maintenance 2.26E-06 - 4.72E-02 8
3 Gene Expression 3.39E-06 - 2.74E-02 14
4 Protein Synthesis 4.88E-06 - 1.74E-02 10
5 Drug Metabolism 7.40E-05 - 3.31E-02 4
6 Small Molecule Biochemistry 7.40E-05 - 3.31E-02 8
7 Dermatological Diseases and Conditions 9.02E-05 - 8.75E-03 7
8 Cell Cycle 1.45E-04 - 3.88E-02 6
9 Neurological Disease 1.49E-04 - 1.61E-02 10
10 Post-Translational Modification 3.36E-04 - 3.74E-02 6
11 Protein Folding 3.36E-04 - 3.48E-02 3
12 Cell Morphology 5.78E-04 - 4.30E-02 9
13 Cellular Assembly and Organization 5.78E-04 - 4.58E-02 8
14 Cell Death and Survival 8.34E-04 - 4.86E-02 13
15 Psychological Disorders 8.35E-04 - 3.14E-02 6
16 Skeletal and Muscular Disorders 8.35E-04 - 4.18E-02 12
17 Cellular Development 1.31E-03 - 3.45E-02 6
18 Skeletal and Muscular System Development and Function 1.31E-03 - 1.02E-02 4
19 Tissue Development 1.31E-03 - 4.72E-02 7
20 Cancer 1.46E-03 - 5.00E-02 19
21 Cardiovascular Disease 1.46E-03 - 2.61E-02 5
22 DNA Replication, Recombination, and Repair 1.46E-03 - 4.86E-02 6
23 Developmental Disorder 1.46E-03 - 2.89E-02 7
24 Embryonic Development 1.46E-03 - 3.60E-02 5
25 Hematological Disease 1.46E-03 - 4.16E-02 9
26 Hereditary Disorder 1.46E-03 - 2.89E-02 6
27 Immunological Disease 1.46E-03 - 4.18E-02 12
28 Nervous System Development and Function 1.46E-03 - 4.86E-02 4
29 Organ Morphology 1.46E-03 - 4.16E-02 4
30 Organismal Development 1.46E-03 - 4.16E-02 4
31 Organismal Injury and Abnormalities 1.46E-03 - 5.00E-02 21
32 Respiratory Disease 1.46E-03 - 4.58E-02 5
33 Tissue Morphology 1.46E-03 - 4.72E-02 4
34 Reproductive System Disease 1.68E-03 - 5.00E-02 11
35 RNA Post-Transcriptional Modification 1.77E-03 - 2.78E-02 4
The table lists the biological functions and diseases identified by IPA as the most significantly influenced by D6 activity (p value ≤0.005, >2 identified molecules).
p-values are reported as range of values referred to the several sub-groups classified by IPA into each bio-functions and disease major group. Bio-functions and
diseases found statistically significant also by the gene expression profile analysis (p value ≤0.001) are shown in bold characters [10]
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treatments. Among the top bio-functions related to the
action of D6 on LB cells, we found several cell processes
involved in cell functions, maintenance, and survival, in-
cluding gene expression and protein synthesis, as well as
cell cycle, cell death and cancer (Table 4), thus demon-
strating D6 interference with key cell activities.
Table 5 reports the canonical pathways that appeared
significantly influenced by changes in protein abundance
subsequent to the D6 treatment in MM cells. These
mostly reflect the main responses of the cell to D6 already
highlighted by expression profiling [10]: involvement of
both cellular stress response (pathways 1, 2, 4, 5, 8) and
cell growth and proliferation related processes (pathways
3, 6–11).
Table 6 lists the two major protein networks related to
D6 treatment, according to IPA analysis. Again, they
show the interference of D6 activity with important cel-
lular processes. The first one evidences the intersections
between the two most represented groups of modulated
proteins listed in Table 3 (stress response and mRNA
processing/translation) with all the correlations elapsing
among molecules involved in RNA processing and pro-
tein synthesis and molecules involved in cell response to
injuries and abnormalities. The second network under-
lines the involvement of cell signaling and cell-to-cell
interaction. Figure 3 shows the intersections among the
two networks and the predicted distribution of the
protein network members according to their cellular
localization.
Discussion
The analysis of the protein complement expressed by a
cell in a given moment or condition gathers information
on the real potential expressed by the genome. In fact,
gene expression analysis, although offering the advantage
of a wider coverage, is biased by the vast plethora of
variables that come into play after gene transcription,
such as the different half lives of transcripts, their tran-
scriptional efficiency, as well as the different half lives of
proteins within the cell. By directly measuring protein
abundances, differential proteomics has the advantage of
providing a more realistic picture of the cell response to
a given stimulus, although the number of proteins that
can be evaluated is often lower than the one obtained in
a transcriptomic study. In a recent paper, we described
the changes induced by D6 treatments in the gene ex-
pression profile of LB24Dagi MM cells [10]. In order to
integrate and validate those findings, a differential prote-
omics study was carried out, and it is described here.
When comparing the list of proteins modified by the D6
treatment with the results of the microarray gene expres-
sion profiling, only 10 direct correspondences were ob-
served: upregulation of six HSPs, Ubiquitin, and YWHAE,
and downregulation of SYNCRIP and HIST1H2AC
(bolded in Tables 1 and 2). Despite the short list of over-
lapping IDs between microarray and proteome differential
analyses, pathways and network analysis using IPA soft-
ware pointed out the alteration of similar biological
functions and molecular pathways in D6 treated MM cells
(see Tables 4 and 5). Moreover, the 10 common IDs ob-
served between the two approaches can be well framed in
the global scenario resulting from IPA bio-functions and
pathways analyses, as discussed below. In fact, it is becom-
ing evident that transcriptomics and proteomics data do
not have often a clear overlap in protein identities, but
these can share the same functional content, that can be
evidenced by extracting information in terms of protein
interaction networks and pathways [44, 45].
The most significant result of the differential proteomic
analysis is a confirmation of a stress induced cell response,
as previously observed at the gene expression level [10].
Indeed, current pathway analysis results indicate the
Table 5 IPA top canonical pathways
Ingenuity canonical pathways -log(B-H p-value) Molecules
1 Protein Ubiquitination Pathway 5,52E00 HSPB1,HSPA1L,DNAJB1,HSPH1,HSPA6,HSPE1,UBC
2 Aldosterone Signaling in Epithelial Cells 5,52E00 HSPB1,HSPA1L,DNAJB1,HSPH1,HSPA6,HSPE1
3 EIF2 Signaling 5,19E00 RPL17,RPL24,RPS27,RPS11,RPL26,RPS3
4 Huntington’s Disease Signaling 3,43E00 HSPA1L,DNAJB1,GNB2L1,HSPA6,UBC
5 Unfolded protein response 2,98E00 HSPA1L,HSPH1,HSPA6
6 14-3-3-mediated Signaling 2,06E00 TUBA1B,YWHAE,YWHAZ
7 Regulation of eIF4 and p70S6K Signaling 1,85E00 RPS27,RPS11,RPS3
8 Cell Cycle: G2/M DNA Damage Checkpoint Regulation 1,65E00 YWHAE,YWHAZ
9 mTOR Signaling 1,65E00 RPS27,RPS11,RPS3
10 Myc Mediated Apoptosis Signaling 1,59E00 YWHAE,YWHAZ
11 ERK5 Signaling 1,56E00 YWHAE,YWHAZ
The table lists the canonical pathways identified by IPA as the most significantly involved in D6 biological effects (−logp-value ≤1.5 after multiple testing correction
according to Benjamini Hochberg). Pathways found statistically significant also by the gene expression profile analysis (p value ≤0.001) are shown in bold characters [10]
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strong involvement of stress induced molecular pathways
(Table 5: pathways 1, 2, 4, 5 and 8), three of which (1, 2, 8)
were also found to be significantly modified in our previ-
ous gene expression profiling [10]. The up-regulation of
eight proteins belonging to the HSPs family (six in com-
mon with the gene expression analysis) is consistent with
this observation; in addition, it suggests the involvement
of protein processing mechanisms in the endoplasmic
reticulum and stimulation of apoptotic pathways as one of
the major D6 effects on MM cells [22, 23]. Moreover, pro-
teins PPIB and PDIA4, also involved in the protein pro-
cessing inside the endoplasmic reticulum [29, 30],
appeared to be down-regulated (Table 2), thus confirming
the influence of D6 on this process. Abundance of ubiquitin
and the significance of pathway 1 (Protein ubiquitination)
involvement (Table 5) could be related to an increase in
protein degradation processes due to severe protein
damage in stressed cells committed to apoptosis, beside of
the central role of the ubiquitination process in cell
cycle regulation [46]. It has been largely demonstrated
that an intense crosstalk exists between the apoptotic
pathways and the ubiquitin and proteasome system
whose function in apoptosis appears to be very com-
plex (reviewed in [24]).
The reduced levels of H2AX and H2AZ, histone H2A
variants involved in DNA repair and regulation of tran-
scription [25–27], instead could be related to a decrease
of transcription activity and to the lack of DNA repair-
ing needs in apoptotic cells.
Such results highlight the activation of a complex anti-
stress molecular network as a cell response to D6
activity. In order to maintain a stable intracellular envir-
onment, cells utilize complex and specialized defense
systems against various type of external perturbations,
activating many adaptive mechanisms that appear to
operate through gene regulatory networks [47]. This
complex molecular response certainly gives rise to alter-
ation of several processes deeply modifying cell behavior
and producing changing in protein expression, as we
observed in our experimental model. The abundance of
YWHAE and YWHAZ proteins (Table 1), isoforms of
the 14-3-3 protein that regulate multiple cellular func-
tions via interactions with phosphorylated partners,
could be an aspect of such a response [48]. Indeed,
14-3-3 proteins act as integrators of various signals that
influence cell fate decisions and tumorigenesis, regulating
apoptosis, mitogenic and stress signaling, and cell-cycle
progression [31]. In our system, their up-regulation is as-
sociated with activation of several pathways involved in
cell cycle control and apoptosis (see Table 5, pathways
6 -14-3-3 mediated signaling, 8 -Cell Cycle: G2/M
DNA Damage Checkpoint Regulation, 10 -Myc Mediated
Apoptosis Signaling, 11 -ERK5 signaling), thus attesting
the activation of a complex molecular signaling network.
Figure 3 shows the diagram elaborated by IPA, which
schematizes the molecular network created by D6 activity
in our MM in vitro model.
The interference of D6 activity with several intracellular
processes regulating cell proliferation and survival is well
evidenced by the results of IPA bio-functions analysis
(Table 4). Indeed, bio-functions such as Gene expression,
Protein synthesis, Cell cycle, Cell Death and Survival were
found significantly influenced by D6 induced proteomic
changes (Table 4).
These results are tightly consistent with those presented
in our previous papers, which pointed out the involvement
of similar bio-functions and molecular pathways, and dem-
onstrated that D6 causes a cell cycle arrest at the G2/M
phase and drives cells to apoptosis [9, 10]. Both cell cycle
arrest and apoptosis are obviously accompanied by a de-
crease or even by a complete block of protein synthesis
[49], which in the present study is evidenced by a de-
creased level of several proteins participating in mRNA
processing and in translation. In fact, three HNRNPs
(HNRNPM, SYNCRIP, RALY) and the RNA helicase
DDX17, all involved in splicing, polyadenylation and other
aspects of mRNA maturation and transport [34, 35, 37, 38]
were found to be downregulated (Table 2). Moreover, four
ribosomal proteins (RPL24, RPL17, RPL26, RPS11), com-
ponents of either 60S or 40S ribosomal subunits [32], and
Table 6 IPA top networks
ID Molecules in network Score Focus molecules Top diseases and functions
1 14-3-3, 60S ribosomal subunit, Actin, Alpha tubulin, DNAJB1, ERK1/2,
GNB2L1, H2AFX, H2AFZ, Histone h3, HNRNPM, HSP, HSP70, Hsp90,
HSPA6, HSPA1L, HSPB1, HSPE1, HSPH1, LDHB, PDIA4, PPIB, 40S
ribosomal subunit, Rnr, RPL17, RPL24, RPL26, RPS3, RPS11, RPS27,
SYNCRIP, TUBA1B, UBC, YWHAE, YWHAZ
67 26 Protein Synthesis, Cellular Compromise,
Cellular Function and Maintenance
2 Akt, ARHGAP28, CD3, CDH22, DPYSL5, EEF1D, GFPT2, HIST1H2AC,
HIST1H2AD, HIVEP3, HMGN2, HSF1, HSPA7, Immunoglobulin, Jnk,
NFkB (complex), Olfr1508, OTULIN, p85 (pik3r), Pkc(s), PSEN1, RELA,
RNF25, RNF141, RNF19B, SEC14L2, SLC6A1, SNRPD3, TCR, TMOD2,
TSTA3, VDAC3, ZFAND5, ZFAND6, ZNF274
12 6 Cell-To-Cell Signaling and Interaction,
Nervous System Development and Function,
Cell Signaling
The table lists the two major protein networks (score >10) related to D6 activity on MM cells identified by IPA analysis. Networks are scored based on the number
of dataset molecules they contain (“Focus molecules” column). The higher the score, the lower the probability of finding the observed number of dataset
molecules in a given network by random chance. Molecules observed in this study are reported in bold characters in the column “molecules in network”
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the translational regulator BZW2 [39], were all detected
as decreased in D6 treated cells, thus confirming a down-
regulation of the protein translation process. Instead,
RPS3 [28] and GNB2L [36], both components of 40S
ribosome subunit, as well as SNRPD3, a component of the
spliceosome [33], appeared to be up-regulated, probably
just because of a general deregulation of survival processes.
The interference of D6 activity with translation and
protein synthesis process is also depicted by the pathway
analysis results (Table 5), where pathways three (EIF2
signaling), seven (eIF4 signaling) and nine (mTOR
signaling), are all related to translation and protein syn-
thesis [50, 51].
Taken together, the data obtained as a result of the dif-
ferential proteomic analysis in D6 treated melanoma
cells generally confirm our previous findings on gene ex-
pression profiling in the same conditions, even if we did
not find a precise correlation among the specific mole-
cules detected with the two approaches. In fact, it should
be noted that, apart from HSPs and few others proteins
Fig. 3 D6 activity molecular network. The diagram shows merging of network 1 and 2 and schematizes the predicted distribution of the protein
networks members according to their cellular localization. Up-regulated proteins are represented in red gradations, while down-regulated ones in green
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related to cell stress response, none of the proteins cor-
responding to the genes whose expression was strongly
modulated by D6 was found to be significantly modu-
lated at the protein level. Such a discrepancy might be
explained by differences in specificity and sensitivity
between the two approaches, as well as by the wealth of
complex molecular mechanisms underlying mRNA and
protein degradation and turnover. In order to go deep
into this aspect, specific protein expression changes
highlighted in this paper are currently being investigated
through western blot analysis and will be included in a
future publication.
Conclusions
In conclusion, the most significant differentially modu-
lated proteins following D6 treatment in cultured melan-
oma cells are represented by proteins involved in stress
cell response (up modulated) and in translation (down
modulated). HSPs are the mainly affected protein family.
This is consistent with our previous findings and with
the biological effects of D6 on MM cells; in fact, HSPs
have a protective function in stress conditions but also
an essential role in apoptosis regulation, which is one of
the D6 mechanisms underlying tumor growth inhibition.
Bio-functions and pathways analyses by IPA pointed out
the involvement of cellular processes strictly associated
to stress and damage cell response, which, in turn, acti-
vate a molecular network involving decrease of protein
synthesis and reduction of vital cell activity. These dra-
matic changes in the cellular environment finally ap-
peared responsible of the cell proliferation arrest and
apoptosis observed in our MM model after D6 treat-
ments. Taken together, our results are in agreement with
the ones obtained with the gene expression profile ana-
lysis, thus confirming the efficacy of D6 as a promising
anti-melanoma agent. In this sense, its large spectrum
activity makes it a good candidate to be considered in
combination therapies with targeted agents, offering a
therapeutic option toward the reduction of drug resist-
ance and disease recurrence.
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